Allarity Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Allarity Therapeutics, Inc. (Nasdaq: ALLR) on January 17, 2023, covering events as of January 13, 2023. The company is an emerging growth company incorporated in Delaware with principal executive offices in Boston, MA.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure updates.
Material Changes
- Common Stock Outstanding: As of January 13, 2023, the company had 18,367,757 shares of common stock outstanding.
- Recent Issuances: Since December 2021, the company issued 10,291,933 shares of common stock resulting from the exercise and conversion of 6,965 shares of Series A Preferred Stock.
- Preferred Stock: As of January 13, 2023, 13,035 shares of Series A Preferred Stock remained issued and outstanding.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or discussion of contingencies and unusual items. It is a routine disclosure of share count changes under Item 8.01 (Other Events).
Investor Verification Checklist
- Verify the total share count of 18,367,757 common shares outstanding as of January 13, 2023.
- Confirm the conversion ratio and terms regarding the 6,965 shares of Series A Preferred Stock converted since December 2021.
- Review the remaining 13,035 shares of Series A Preferred Stock for potential future dilution or conversion rights.